Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.5491
+0.0031 (0.57%)
Mar 13, 2026, 10:41 AM EDT - Market open
Jaguar Health Employees
Jaguar Health had 49 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
49
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$240,510
Profits / Employee
-$822,306
Market Cap
2.49M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 49 | 0 | - |
| Dec 31, 2023 | 49 | -11 | -18.33% |
| Dec 31, 2022 | 60 | 8 | 15.38% |
| Dec 31, 2021 | 52 | 18 | 52.94% |
| Dec 31, 2020 | 34 | 5 | 17.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Scinai Immunotherapeutics | 31 |
| Lyra Therapeutics | 30 |
| Calidi Biotherapeutics | 28 |
| CDT Equity | 6 |
| Enveric Biosciences | 6 |
| CNS Pharmaceuticals | 5 |
| PMGC Holdings | 3 |
| 60 Degrees Pharmaceuticals | 3 |
JAGX News
- 2 days ago - Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts - Accesswire
- 4 days ago - Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants - Accesswire
- 10 days ago - Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1 - Accesswire
- 11 days ago - Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend - Accesswire
- 23 days ago - Jaguar Health Announces a Special One-time Stock Dividend - Accesswire
- 7 weeks ago - Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi - Accesswire
- 2 months ago - Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts - Accesswire
- 2 months ago - Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million - Accesswire